Results 101 to 110 of about 1,472 (172)

Omadacycline in the Treatment of Mycobacterium abscessus Infection

Clinical Infectious Diseases, 2019
openaire   +2 more sources

Flow cytometry enables rapid evaluation of novel, new and niche antimicrobial agents. [PDF]

Front Microbiol
Salisbury E, Mulroney K, Kopczyk MK, Paton T, Carson CF, Ho WS, Chakera A.   +6 more
europepmc   +1 more source

Clinical Outcomes of Omadacycline in Critically Ill Patients Treated for Carbapenem-Resistant Organism Infections: A Retrospective Study. [PDF]

Infect Drug Resist
Chen N, Xu Q, Song R, Luo Y, Xie L, Zhou J, Wang X.   +6 more
europepmc   +1 more source

Omadacycline, a Magic Antibiotics for Bacterial Infections

Journal of Bacteriology and Virology, 2018
Mohammad Saydur Rahman, Young-Sang Koh
openaire   +1 more source

Efficacy and Safety of Tetracyclines in Bone and Joint Infections: A Literature Review. [PDF]

Infect Dis Ther
Laffont-Lozes P, Larcher R, Artiaga A, Lavigne JP, Loubet P, Sotto A.   +5 more
europepmc   +1 more source

Systematic and quantitative analyses of hollow fiber model of <i>Mycobacterium abscessus</i> lung disease studies and new dosing recommendations. [PDF]

Microbiol Spectr
Srivastava S, Gumbo T.
europepmc   +1 more source

Erratum: Comparative in vitro Activity and Clinical Outcomes of Eravacycline, Tigecycline, and Omadacycline Against Carbapenem-Resistant <i>Acinetobacter baumannii</i> and <i>Klebsiella pneumoniae</i> [Corrigendum]. [PDF]

Infect Drug Resist
europepmc   +1 more source

Preclinical <i>in vitro</i> and <i>in vivo</i> evaluation of omadacycline against multidrug-resistant <i>Acinetobacter baumannii</i>. [PDF]

Antimicrob Agents Chemother
Vanachayangkul P, Ruamsap N, Caridha D, Imerbsin R, Ball E, Chattagul S, Tungtang A, Gonwong S, Kodchakorn C, Lertsethtakarn P, Silapong S, Chaisatit C, Khemnu N, Boudreaux D, Boonyalai N, Demons S, Pierce JV, Martin M, Anastasiou D, Serio AW, Vesely B, Lanteri CA.   +21 more
europepmc   +1 more source

Sulbactam-durlobactam plus ceftriaxone dosing and novel treatment regimens for <i>Mycobacterium abscessus</i> lung disease. [PDF]

Antimicrob Agents Chemother
Singh S, Shrivastava A, Boorgula GD, Long MC, Robbins B, McShane PJ, Gumbo T, Srivastava S.   +7 more
europepmc   +1 more source

Faecal pharmacokinetics, microbiome, and bile acid changes in healthy subjects given intravenous followed by oral omadacycline; a Phase 1 clinical trial. [PDF]

J Antimicrob Chemother
Jo J, Carlson TJ, Hu C, Williamson JC, Belin YT, Horvath TD, Haidacher SJ, Bassères E, Begum K, Alam MJ, Garey KW.   +10 more
europepmc   +1 more source